Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol. 2022 Jan; 101(1):131-137.